Contattaci Contact Us

WEBINAR Detail:

Virtual Round Table on NEW BIOLOGICAL INSIGHTS AND NOVEL DRUGS IN ACUTE LEUKEMIA

Subscription:
Free
Date:
20/11/2020
Venue:
Platform:

LIVE STREAMING on Fondazione Menarini's Website or APP




Immersive Experience in the 3D World

We are pleased to invite you for a uniqueeasy and engaging new communication experience:

the Round Table on NEW BIOLOGICAL INSIGHTS AND NOVEL DRUGS IN ACUTE LEUKEMIA” in 3D!




Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are clonal disorders resulting from acquired somatic mutations in hematopoietic progenitor cells that lead to the dysregulation of differentiation and proliferation of hematopoietic cells.

AML and ALL are heterogeneous diseases with respect to presentation and clinical outcome.

An increasing understanding of molecular aberrations that trigger the development of acute leukemia, and growing use of next generation sequencing, are advancing the development of investigational drugs targeting driver genetic mutations.


This round table debate will focus on novel diagnostic and therapeutic tools for the management of AML and ALL. The role of minimal residual disease detection for a sharper management of acute leukemia will be highlighted.




Co-presidents:

Francesco Lanza

Section of Hematology &
Romagna Metropolitan Transplant Network
Hospital of Ravenna
Ravenna, IT


Giovanni Martinelli

Istituto Scientifico Romagnolo per lo Studio
e la Cura dei Tumori (I.R.S.T.)
Meldola - FC, IT


Reserved area

APP FONDAZIONE MENARINI



Pills of Art Menarini

“Pills of Art”
A new multimedia project dedicated to the art world.



New Projects: MINUTI DIGITALE



Minuti Menarini Online

Subscribe for free to the paper version of the magazine



Fondazione Menarini



SIGN UP FOR THE NEWSLETTER

Receive information about the Fondazione Menarini every month.

VGFM DATA-LAYER

Fondazione Menarini
Fondazione Menarini, Centro Direzionale Milanofiori 20089 Rozzano (MI) - Edificio L - Strada 6
Tel. +39 02 55308110 Fax +39 02 55305739 C.F. 94265730484